Based on these experimental data, as well as our finding that patients with tumor PD‐L1 positivity and high platelet counts experienced poor outcomes, it may be possible to utilize platelets during anti‐PD‐L1 therapy (eg, with conjugated antibodies to PD‐L1) in order to prevent postoperative recurrence. The gene discussed is CD274; the disease is neoplasm.